Psychedelics and Autism Therapy: A Review of Current Research and Future Directions
Current Issues in Molecular Biology April 18, 2026 Christopher S. Gondi, Manu Gnanamony, Tarun P. Gondi et al.
Psychedelics such as LSD, psilocybin, and MDMA show promise for treating autism spectrum disorder by promoting neuroplasticity—the brain's ability to change and adapt. These substances modulate serotonin 5-HT2A receptors and interact with other serotonergic, dopaminergic, and glutamatergic pathways, leading to structural and functional brain changes that may enhance social behavior and emotional regulation. Studies indicate psychedelics can reduce symptoms of treatment-resistant depression and PTSD, and for autism specifically, may improve psychological flexibility, reduce distress, and enhance social interaction. However, their use requires careful monitoring and ethical oversight due to intense experiences and altered states of consciousness.